Anti Vegf Use In Ophthalmology

The introduction of anti-vascular endothelial growth factor (VEGF) agents has revolutionized therapy for a host of ocular diseases associated with leakage from normal blood vessels and pathologic blood vessel growth. Anti-VEGF Use in Ophthalmology is an all-inclusive reference designed to provide detailed, up-to-date, and clinically relevant information on the current use of anti-VEGF agents in the treatment of all ocular conditions. Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use. The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents. Some of the topics covered in Anti-VEGF Use in Ophthalmology: Neovascular Age-Related Macular Degeneration Proliferative Diabetic Retinopathy Retinal Vein Occlusion Uveitis Neovascular Glaucoma Macular Edema Retinopathy of Prematurity Corneal Disease Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease.

The introduction of anti-vascular endothelial growth factor (VEGF) agents has revolutionized therapy for a host of ocular diseases associated with leakage from normal blood vessels and pathologic blood vessel growth. Anti-VEGF Use in Ophthalmology is an all-inclusive reference designed to provide detailed, up-to-date, and clinically relevant information on the current use of anti-VEGF agents in the treatment of all ocular conditions. Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use. The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents. Some of the topics covered in Anti-VEGF Use in Ophthalmology: Neovascular Age-Related Macular Degeneration Proliferative Diabetic Retinopathy Retinal Vein Occlusion Uveitis Neovascular Glaucoma Macular Edema Retinopathy of Prematurity Corneal Disease Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease.

The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration. Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization. The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.

Recently developed diagnostic and therapeutic technologies such as OCT-angiography and small gauge vitrectomy have influenced the modern treatment of diabetic retinopathy. This volume provides a summary of the state-of-the-art evidence-based approach to managing complications that may occur with diabetic retinopathy. It offers the latest information on pathogenesis and diagnosis, and highly experienced clinicians review the results of relevant randomized clinical trials that serve as the basis of current therapy. The book provides not only a summary of data from randomized trials but also an analysis and interpretation by internationally renowned experts. Ophthalmology residents, fellows, and practicing clinicians will find this book to be a useful reference when seeking evidence-based treatment strategies for various complications of diabetic retinopathy. It is also for researchers identifying new avenues of drug developments and for insurance professionals and health care policy administrators who are establishing evidence-based therapy guidelines for therapeutic intervention.

Diabetic retinopathy (DR), a common microvascular complication, has consistently been shown to be associated with an increased risk of cardiovascular disease (CVD). This book provides complete coverage of DR as a potential marker for CVD in those with diabetes. It succinctly reviews the epidemiological and pathogenic links of DR to various cardiovascular events including stroke, coronary artery disease, chronic kidney disease, heart failure, and mortality. Furthermore, it discusses the usefulness of DR in CVD risk prediction and cardiovascular safety of anti-VEGF therapy in diabetic patients. There are insights from contemporary diabetic trials that demonstrated the enhanced cardiovascular benefit of novel glucose lowering therapy. It also highlights the potential of novel retinal imaging to predict CVD and its risk factors using the state-of-the art artificial intelligence-based deep learning systems. This book will be an invaluable resource for specialists translating research findings into clinical care, including those in cardiology, endocrinology, ophthalmology, and general practitioners. IT will also be of interest to public health practitioners, researchers, graduate students, and biotech companies interested in developing retinal image-based diagnostic and prognostic tools.

This open access book provides a comprehensive overview of the application of the newest laser and microscope/ophthalmoscope technology in the field of high resolution imaging in microscopy and ophthalmology. Starting by describing High-Resolution 3D Light Microscopy with STED and RESOLFT, the book goes on to cover retinal and anterior segment imaging and image-guided treatment and also discusses the development of adaptive optics in vision science and ophthalmology. Using an interdisciplinary approach, the reader will learn about the latest developments and most up to date technology in the field and how these translate to a medical setting. High Resolution Imaging in Microscopy and Ophthalmology – New Frontiers in Biomedical Optics has been written by leading experts in the field and offers insights on engineering, biology, and medicine, thus being a valuable addition for scientists, engineers, and clinicians with technical and medical interest who would like to understand the equipment, the applications and the medical/biological background. Lastly, this book is dedicated to the memory of Dr. Gerhard Zinser, co-founder of Heidelberg Engineering GmbH, a scientist, a husband, a brother, a colleague, and a friend.

This book provides a comprehensive account of the pathogenesis, clinical features, and management of ocular vascular occlusive disorders, with the focus very much on the scientific evidence. This offers a sound basis for addressing the many controversies that surround these disorders, which collectively constitute the most common cause of visual impairment or blindness. The book is divided into two sections, the first of which addresses the basic science and encompasses vascular anatomy, blood supply and flow, and retinal tolerance time to acute ischemia. The second, clinical, section covers the presentation, clinical features, diagnosis, and treatment of the full range of vascular occlusive disorders of the retina, the choroid, the anterior segment of the eye, ophthalmic manifestations of carotid artery disease and the optic nerve. Ocular Vascular Occlusive Disorders, written by a distinguished world leader in the field, will be invaluable for general ophthalmologists, and particularly for retina specialists, neuro-ophthalmologists, and researchers.

The most comprehensive text and definitive guide for nearly 30 years about optical coherence tomography (OCT) imaging in ophthalmology, Optical Coherence Tomography of Ocular Diseases, Fourth Edition covers a range of subjects, from principles and operation techniques to clinical interpretation and the latest innovations in OCT. Written by the pioneers of OCT technologies and the world-renowned OCT researchers Drs. Joel S. Schuman, James G. Fujimoto, Jay S. Duker, Hiroshi Ishikawa, and Gadi Wollstein, Optical Coherence Tomography of Ocular Diseases, Fourth Edition is an essential text for imaging technology. OCT now occupies a dominant role as a diagnostic tool for retinal conditions and glaucoma. At the same time, the technology continues to show potential for emerging clinical and research applications across all the ophthalmological subspecialties. To reflect these rapid advances, this new edition of Optical Coherence Tomography of Ocular Diseases features a complete and thorough revision of the existing text as well as the addition of cutting-edge content to bring this classic resource completely up to date. New content in the Fourth Edition includes: • OCT angiography • Swept-source OCT • OCT in multimodal imaging • Clinical utility of OCT in glaucoma prediction and progression detection • OCT for neuro-ophthalmology Optical Coherence Tomography of Ocular Diseases, Fourth Edition is the one and only book needed by practitioners who use OCT for clinical eye care.

Chandler and Grant’s Glaucoma—one of the field’s seminal texts on the medical practice and surgical management of glaucoma, now in its Sixth Edition—includes the latest updates in an area that is currently experiencing a surge of innovation. Edited by Drs. Malik Y. Kahook and Joel S. Schuman and with writings from the late Dr. David L. Epstein and more than 80 contributors, Chandler and Grant’s Glaucoma, Sixth Edition brings together the experience of world-class glaucoma experts who belong to a long line of surgeons trained using the teachings of the original authors of this classic work. Each chapter has been meticulously edited and updated from the previous edition, while maintaining the well-established historical teachings of Drs. Paul A. Chandler and W. Morton Grant. New chapters on medical therapy as well as thorough updates on novel and minimally invasive approaches for the surgical management of glaucoma have been added. New topics and features in the Sixth Edition include: Advances in imaging of the optic nerve and retina Rho-associated protein kinase inhibitors Glaucoma and cerebrospinal fluid pressure The FDA’s role in the development of new diagnostic and surgical devices for patients with glaucoma Chandler and Grant’s Glaucoma has been the most relevant and invaluable reference on glaucoma for generations of ophthalmologists. This updated Sixth Edition builds on the teachings of previous editions, making the Sixth Edition as relevant in the 21st century as when the first lectures were presented by Drs. Chandler and Grant more than 55 years ago.